Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism

Clinical Pharmacology and Therapeutics

Volumn 76, Issue 6, 2004, Pages 598-606

  Granfors, Marika T ^a   Backman, Janne T ^a,b   Neuvonen, Mikko ^a   Neuvonen, Pertti J ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CIPROFLOXACIN; CYTOCHROME P450 1A2; PARAXANTHINE; TIZANIDINE;

ADULT; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFECT; DRUG METABOLISM; HUMAN; HYPOTENSION; MALE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ADULT; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BLOOD PRESSURE; CAFFEINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIPROFLOXACIN; CLONIDINE; CYTOCHROME P-450 CYP1A2; ENZYME INHIBITORS; HALF-LIFE; HEART RATE; HUMANS; MUSCLE RELAXANTS, CENTRAL; PHOSPHODIESTERASE INHIBITORS;

EID: 10044260714     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.08.018     Document Type: Article

References (28)

1. A.J. Wagstaff, H.M. Bryson Tizanidine: a review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders Drugs 53 1997 435 452
2. A.E. Lake III, J.R. Saper Chronic headache New advances in treatment strategies Neurology 59 Suppl 2 2002 S8 S13
3. P. Koch, D.R. Hirst, B.R. von Wartburg Biological fate of sirdalud in animals and man Xenobiotica 19 1989 1255 1265
4. F.L.S. Tse, J.M. Jaffe, S. Bhuta Pharmacokinetics of orally administered tizanidine in healthy volunteers Fundam Clin Pharmacol 1 1987 479 488
5. M.T. Granfors, J.T. Backman, J. Laitila, P.J. Neuvonen Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro Br J Clin Pharmacol 57 2004 349 353
6. M.T. Granfors, J.T. Backman, M. Neuvonen, J. Ahonen, P.J. Neuvonen Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction Clin Pharmacol Ther 75 2004 331 341
7. R. Davis, A. Markham, J.A. Balfour Ciprofloxacin An updated review of its pharmacology, therapeutic efficacy and tolerability Drugs 51 1996 1019 1074
8. R.J. Bertz, G.R. Granneman Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions Clin Pharmacokinet 32 1997 210 258
9. W.J. Wijnands, T.B. Vree, C.L. van Herwaarden The influence of quinolone derivatives on theophylline clearance Br J Clin Pharmacol 22 1986 677 683
10. K.T. Batty, T.M. Davis, K.F. Ilett, L.J. Dusci, S.R. Langton The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects Br J Clin Pharmacol 39 1995 305 311
11. S. Harder, A.H. Staib, C. Beer, A. Papenburg, W. Stille, P.M. Shah 4-Quinolones inhibit biotransformation of caffeine Eur J Clin Pharmacol 35 1988 651 656
12. K. Raaska, P.J. Neuvonen Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia Eur J Clin Pharmacol 56 2000 585 589
13. M.J. Jokinen, K.T. Olkkola, J. Ahonen, P.J. Neuvonen Effect of ciprofloxacin on the pharmacokinetics of ropivacaine Eur J Clin Pharmacol 58 2003 653 657
14. C. Dollery Therapeutic drugs 2nd ed 1999 Churchill Livingstone Edinburgh (United Kingdom). p. C230, F139.
15. J.T. Backman, K.T. Olkkola, P.J. Neuvonen Rifampin drastically reduces plasma concentrations and effects of oral midazolam Clin Pharmacol Ther 59 1996 7 13
16. K.T. Olkkola, J.T. Backman, P.J. Neuvonen Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole Clin Pharmacol Ther 55 1994 481 485
17. K.T. Kivistö, J.-S. Wang, J.T. Backman, L. Nyman, P. Taavitsainen, M. Anttila Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole Eur J Clin Pharmacol 57 2001 37 42
18. U. Fuhr, K.L. Rost, R. Engelhardt, M. Sachs, D. Liermann, C. Belloc Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations Pharmacogenetics 6 1996 159 176
19. O. Spigset, S. Hägg, E. Söderström, R. Dahlqvist The paraxanthine:caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained? Pharmacogenetics 9 1999 409 412
20. M.T. Maya, N.J. Goncalves, N.B. Silva, J.A. Morais Simple high-performance liquid chromatographic assay for the determination of ciprofloxacin in human plasma with ultraviolet detection J Chromatogr B 755 2001 305 309
21. D.T. Holland, K.A. Godfredsen, T. Page, J.D. Connor Simple high-performance liquid chromatography method for the simultaneous determination of serum caffeine and paraxanthine following rapid sample preparation J Chromatogr B 707 1998 105 110
22. C.E. Pickard, A.D. Stewart, R. Hartley, M.D. Lucock A rapid HPLC method for monitoring plasma levels of caffeine and theophylline using solid phase extraction columns Ann Clin Biochem 23 1986 440 446
23. X. Ding, L.S. Kaminsky Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts Annu Rev Pharmacol Toxicol 43 2003 149 173
24. Product information for Zanaflex. Available from: URL:http://www.acorda. com/Zanaflex_Insert.pdf. Accessed Aug 7, 2004.
25. C. Dollery Therapeutic drugs 2nd ed 1999 Churchill Livingstone Edinburgh (United Kingdom). p. C4.
26. S. Härtter, C. Ursing, S. Morita, G. Tybring, C. von Bahr, M. Christensen Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study Clin Pharmacol Ther 70 2001 10 16
27. Finnish Statistics on Medicines 2002. Helsinki (Finland): National Agency for Medicines and Social Insurance Institution. 2003.
28. Biospace News. Available from: URL:http://www.biospace.com/news_story. cfm?StoryID=13914420&full=1. Accessed Aug 7, 2004.